Agomab initiated with an Outperform at Leerink

Leerink analyst Thomas J. Smith initiated coverage of Agomab (AGMB) with an Outperform rating and $36 price target With potentially value-inflecting readouts ahead, growing strategic interest in anti-fibrotics and inflammatory bowel disease, along with sufficient capital to reach these key milestones, the firm believes Agomab is entering a milestone-rich 2026 with meaningful upside potential and the opportunity to become an important player in IBD and broader anti-fibrotic indications.